Compare SA & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | AVDL |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | SA | AVDL |
|---|---|---|
| Price | $29.67 | $21.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $65.00 | $18.38 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $248,517,000.00 |
| Revenue This Year | N/A | $65.47 |
| Revenue Next Year | N/A | $30.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 79.88 |
| 52 Week Low | $9.40 | $6.38 |
| 52 Week High | $31.87 | $23.57 |
| Indicator | SA | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 60.27 |
| Support Level | $28.31 | $21.36 |
| Resistance Level | $31.87 | $21.67 |
| Average True Range (ATR) | 1.44 | 0.12 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 48.90 | 70.89 |
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.